Woodcock steps in at CDER as Galson departs

Share this article:
To help it implement new FDA reform legislation signed into law in September, the Bush administration has shaken up the leadership of the agency's drug center, whose flounderings over product safety more than anything else provoked passage of the FDA Amendments Act.

Drug center director Steven Galson was elevated to acting surgeon general.

His predecessor, FDA deputy commissioner and chief medical officer Janet Woodcock, who held the post for over a decade until 2005, has returned to the position on a temporary basis.

Galson's tenure was characterized by major public turbulence on the subordination of drug safety reviews to new drug-approval reviews, which he tried to reverse, the Vioxx and David Graham whistleblower controversy, and the uproar over the Plan B emergency contraceptive OTC switch.
FDA commissioner Andrew von Eschenbach told his employees in an e-mail that a national search for a permanent director for the drug center will begin “immediately.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters